✉ Email this page to a colleague
« Back to Dashboard
Obatoclax is an investigational drug.
There have been 19 clinical trials for Obatoclax. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2012.
The most common disease conditions in clinical trials are Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, and Lung Neoplasms. The leading clinical trial sponsors are Gemin X, National Cancer Institute (NCI), and Cephalon.
Recent Clinical Trials for Obatoclax
|Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer||Cephalon||Phase 3|
|Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma||National Cancer Institute (NCI)||Phase 1/Phase 2|
|Obatoclax for Systemic Mastocytosis||Gemin X||Phase 2|